Sam Young, Jr., PhD, Roper Investigator, Professor of Pediatrics, and Director of the 大象传媒 Gene Therapy Center, has been elected to his second one-year term on the Technical Activities Committee (TAC) of the .
NIIMBL is a public-private partnership dedicated to accelerating biopharmaceutical innovation, developing industry standards for more efficient manufacturing, and fostering a highly skilled biopharmaceutical workforce to strengthen U.S. competitiveness. As part of Manufacturing USA庐, NIIMBL is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) within the U.S. Department of Commerce, alongside substantial support from its members.
The TAC is composed of leading technical experts in bioprocessing. It plays a crucial role in shaping NIIMBL鈥檚 technology projects, proposals, and road-mapping initiatives鈥攅nsuring that industry priorities align with future advancements in biopharmaceutical manufacturing.
Since its establishment in 2017 through a $70 million cooperative agreement with NIST, NIIMBL has significantly impacted the field. In its first six years, North Carolina-based members participated in projects totaling $25.6 million, including $9.3 million in federal funding. Of this:
- $7.8 million supported research at North Carolina universities
- $1.4 million funded small and medium-sized enterprises
- $100,000 went to non-profit organizations
Dr. Young鈥檚 continued engagement will help guide NIIMBL鈥檚 technical strategies, ensuring the industry remains at the forefront of cutting-edge advancements. Congratulations!